Guest: Dr. Atul Deodhar
Presenter: Neal Howard
Guest Bio: Through his role on the Executive Committee of the SpondyloArthritis Research and Treatment Network (SPARTAN), Dr. Deodhar has been dedicated to spondyloarthritis research, including epidemiology, diagnosis, and treatment strategies. He has been engaged in clinical trials assessing the efficacy of novel therapies in ankylosing spondylitis and psoriatic arthritis. Together with the Department of Dermatology, he has created the Center for Psoriasis and Psoriatic Arthritis Excellence (CEPPA) at OHSU, a multidisciplinary clinic which has provided care for patients with psoriasis and psoriatic arthritis and allowed the collection and analysis of a CEPPA registry.
Segment overview: Dr. Atul Deodhar, MD, a lead study investigator with Janssen is here to discuss the results of the Phase 3 GO-ALIVE study with SIMPONI ARIA® (golimumab) infusion for patients with ankylosing spondylitis.
Transcript – TBU